FisherVista

Wire Orthodontics, led by Dr. Clint Wire, has expanded its Liberty Lake location to accommodate growing demand for personalized braces and Invisalign treatments for patients of all ages.

Wire Orthodontics has expanded its orthodontic services to both Spokane and Liberty Lake locations, offering braces and Invisalign for all ages under a unified care model with direct oversight from Dr. Clint Wire.

Search Atlas releases a full-suite SEO platform with OTTO AI, enabling agencies to deliver services under their own brand without manual intervention, consolidating multiple tools into one system.

Twin Vee PowerCats Co. announced a 10% year-over-year revenue increase in the first quarter of 2026, its fourth consecutive quarter of growth, while advancing the relaunch of its Bahama Boat Works luxury brand.

Datavault AI highlights its distributed edge computing strategy ahead of U.S. Senate markup of the Digital Asset Market Clarity Act, expecting regulatory clarity to boost demand for secure data processing and AI infrastructure.

Search Atlas introduces Atlas Agent, an autonomous conversational AI for end-to-end digital marketing, alongside new metrics Domain Power and LLM Visibility to measure brand presence in AI-generated answers.

Cyber Defense Magazine's May 2026 report names small businesses as the fastest-growing attack surface, prompting Ev0-Tech founder Dan Vega to reaffirm his firm's 'Security First' model for SMBs.

Keona Health released ROI guidance and a calculator to help healthcare organizations quantify the financial and operational impact of manual triage versus AI-assisted workflows, revealing potential savings and risk reduction.

A new Footminders survey reveals that over half of workers who stand for long hours suffer from frequent foot pain, but only 22% use orthotic insoles, highlighting a gap in workplace wellness.

SureNano Science has begun a GLP toxicology and pharmacology program for its lead candidate GEP-44, aiming to enter the $200 billion GLP-1 market with a multi-receptor peptide targeting obesity and type 2 diabetes.

Springs Rejuvenation's Atlanta clinic now offers stem cell exosome therapy, advanced FUE hair restoration, and regenerative joint protocols, providing minimally invasive alternatives to traditional treatments in the Southeast.

MindBio Therapeutics Corp. announced the development of AI-powered fatigue recognition technology that analyzes voice patterns, to be added as a commercial feature to its Edge AI Intoxication Detection Kiosks, targeting high-risk industries like aviation, road transport, and mining.

HeartBeam initiated a pilot study for its investigational patch-based 12-lead ECG device aimed at detecting ischemia, targeting a $2 billion market and expanding ambulatory cardiac monitoring beyond rhythm assessment.

Oncotelic Therapeutics is using a partnership-driven strategy, including a GMP Bio joint venture that added $249 million to its balance sheet, to advance its drug pipeline and AI platform without diluting shareholder value.

SPARC AI Inc. is developing a software-only system for GPS-denied navigation and precision targeting in drones, addressing a critical gap as defense agencies prioritize scalable autonomous systems.

SureNano Science Ltd., through GlucaPharm Inc., is progressing its patented triple agonist peptide GEP-44 for obesity and metabolic diseases, aiming to compete in a market projected to exceed $200 billion.

Innovations in crossing the blood-brain barrier, such as Oncotelic's intranasal nose-to-brain system, are poised to transform treatment for neurological diseases and open new biotech market opportunities.

The copper market is experiencing heightened volatility driven by geopolitical uncertainties rather than traditional supply-demand fundamentals, according to an ING analysis, with implications for mining companies and investors.

SureNano Science Ltd., through its subsidiary GlucaPharm Inc., is developing GEP-44, a novel triple agonist peptide for GLP-1 therapy, aiming to improve efficacy, tolerability, and delivery flexibility in a market dominated by Eli Lilly and Novo Nordisk.